Pardoprunox

Pardoprunox (SLV-308) is a partial dopamine D2 and D3 receptor partial agonist and a serotonin 5-HT1A receptor agonist, with pEC50s of 8, 9.2, and 6.3, respectively[1].

Product Specifications

CAS Number

[269718-84-5]

Product Name Alternative

SLV-308; DU-126891

UNSPSC

12352005

Hazard Statement

H302-H315-H319

Target

5-HT Receptor; Adrenergic Receptor; Dopamine Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Neurological Disease; Endocrinology

Assay Protocol

https://www.medchemexpress.com/Pardoprunox.html

Solubility

10 mM in DMSO

Smiles

O=C1OC2=C(N3CCN(C)CC3)C=CC=C2N1

Molecular Formula

C12H15N3O2

Molecular Weight

233.27

Precautions

P264-P270-P280-P302+P352-P305+P351+P338-P330-P362+P364-P501

References & Citations

[1]Glennon JC, et al. In vitro characterization of SLV308 (7-[4-methyl-1-piperazinyl]-2 (3H) -benzoxazolone, monohydrochloride) : a novel partial dopamine D2 and D3 receptor agonist and serotonin 5-HT1A receptor agonist. Synapse. 2006 Dec 15;60 (8) :599-608.|[2]Bronzova J, et al. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease. Mov Disord. 2010 Apr 30;25 (6) :738-46.|[3]Bétry C, et al. In vivo effects of pardoprunox (SLV308), a partial D?/D? receptor and 5-HT1A receptor agonist, on rat dopamine and serotonin neuronal activity. Synapse. 2011 Oct;65 (10) :1042-51.